Showing results (461-470 of 635) with videos related to
Sort By:
Pageof 64
JACC. Heart Failure|January 4, 2023
Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVERSenthil Selvaraj, Muthiah Vaduganathan, Brian L Claggett, et al.European Journal of Heart Failure|September 30, 2017
Prognostic importance of emerging cardiac, inflammatory, and renal biomarkers in chronic heart failure patients with reduced ejection fraction and anaemia: RED-HF studyPaul Welsh, Lei Kou, Changhong Yu, et al.JACC. Heart Failure|August 26, 2025
Temporal Changes in Biomarkers, Functional Status, and Quality of Life Prior to Adverse Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection FractionHenri Lu, Brian L Claggett, Muthiah Vaduganathan, et al.European Journal of Heart Failure|December 2, 2017
Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HFUlrik M Mogensen, Lars Køber, Pardeep S Jhund, et al.Journal of the American College of Cardiology|August 30, 2022
Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart FailureMuthiah Vaduganathan, Brian L Claggett, Pardeep Jhund, et al.European Journal of Heart Failure|June 9, 2025
Application of a transthyretin amyloid cardiomyopathy score to heart failure with mildly reduced or preserved ejection fractionRiccardo M Inciardi, Muthiah Vaduganathan, Brian Claggett, et al.European Journal of Heart Failure|April 13, 2025
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trialJawad H Butt, Pardeep S Jhund, Alasdair D Henderson, et al.European Journal of Heart Failure|May 16, 2025
Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS-HF trialJonathan W Cunningham, Brian L Claggett, Muthiah Vaduganathan, et al.Journal of the American Heart Association|February 23, 2024
Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA-HF TrialsAnkeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.European Journal of Heart Failure|September 29, 2023
Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fractionShingo Matsumoto, Toru Kondo, Mingming Yang, et al.Pageof 64